Human papillomavirus and cervical cancer

被引:2449
作者
Crosbie, Emma J. [1 ]
Einstein, Mark H. [2 ,3 ]
Franceschi, Silvia [4 ]
Kitchener, Henry C. [1 ]
机构
[1] Univ Manchester, Inst Canc Sci, Manchester, Lancs, England
[2] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Montefiore Med Ctr, Albert Einstein Canc Ctr, Bronx, NY 10467 USA
[4] Int Agcy Res Canc, F-69372 Lyon, France
基金
美国国家卫生研究院; 比尔及梅琳达.盖茨基金会;
关键词
INTRAEPITHELIAL NEOPLASIA; HPV INFECTION; FOLLOW-UP; WOMEN; VACCINE; POPULATION; PERSISTENCE; CYTOLOGY; RISK; DNA;
D O I
10.1016/S0140-6736(13)60022-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cervical cancer is caused by human papillomavirus infection. Most human papillomavirus infection is harmless and clears spontaneously but persistent infection with high-risk human papillomavirus (especially type 16) can cause cancer of the cervix, vulva, vagina, anus, penis, and oropharynx. The virus exclusively infects epithelium and produces new viral particles only in fully mature epithelial cells. Human papillomavirus disrupts normal cell-cycle control, promoting uncontrolled cell division and the accumulation of genetic damage. Two effective prophylactic vaccines composed of human papillomavirus type 16 and 18, and human papillomavirus type 16, 18, 6, and 11 virus-like particles have been introduced in many developed countries as a primary prevention strategy. Human papillomavirus testing is clinically valuable for secondary prevention in triaging low-grade cytology and as a test of cure after treatment. More sensitive than cytology, primary screening by human papillomavirus testing could enable screening intervals to be extended. If these prevention strategies can be implemented in developing countries, many thousands of lives could be saved.
引用
收藏
页码:889 / 899
页数:11
相关论文
共 104 条
  • [91] A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3
    Trimble, Cornelia L.
    Peng, Shiwen
    Kos, Ferdynand
    Gravitt, Patti
    Viscidi, Raphael
    Sugar, Elizabeth
    Pardoll, Drew
    Wu, T. C.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (01) : 361 - 367
  • [92] UK Department of Health, 2012, HPV VACC UPT JUN 201
  • [93] UK Department of Health, 2010, ANN HPV VACC COV ENG
  • [94] Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillornavirus antigens
    van der Burg, Sjoerd H.
    Piersma, Sytse J.
    de Jong, Annemieke
    van der Hulst, Jeanette M.
    Kwappenberg, Kitty M. C.
    van den Hende, Muriel
    Welters, Marij J. P.
    Van Rood, Jon J.
    Fleuren, Gert Jan
    Melief, Cornelis J. M.
    Kenter, Gemma G.
    Offringa, Rienk
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (29) : 12087 - 12092
  • [95] Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response
    van Steenwijk, Peggy J. de Vos
    Piersma, Sytse J.
    Welters, Marij J. P.
    van der Hulst, Jeanette M.
    Fleuren, Gertjan
    Hellebrekers, Bart W. J.
    Kenter, Gemma G.
    van der Burg, Sjoerd H.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (22) : 7188 - 7195
  • [96] Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741
  • [97] Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica
    Wang, SS
    Schiffman, M
    Herrero, R
    Carreon, J
    Hildesheim, A
    Rodriguez, AC
    Bratti, MC
    Sherman, ME
    Morales, J
    Guillen, D
    Alfaro, M
    Clayman, B
    Burk, RD
    Viscidi, RP
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (07) : 1269 - 1274
  • [98] Detection of human papillomavirus type 18 E6 and E7-specific CD4+T-helper 1 immunity in relation to health versus disease
    Welters, MJP
    van der Logt, P
    van den Eeden, SJF
    Kwappenberg, KMC
    Drijfhout, JW
    Fleuren, GJ
    Kenter, GG
    Melief, CJM
    van der Burg, SH
    Offringa, R
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (04) : 950 - 956
  • [99] Welters MJP, 2003, CANCER RES, V63, P636
  • [100] Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
    Wheeler, Cosette M.
    Castellsague, Xavier
    Garland, Suzanne M.
    Szarewski, Anne
    Paavonen, Jorma
    Naud, Paulo
    Salmeron, Jorge
    Chow, Song-Nan
    Apter, Dan
    Kitchener, Henry
    Teixeira, Julio C.
    Skinner, S. Rachel
    Jaisamrarn, Unnop
    Limson, Genara
    Romanowski, Barbara
    Aoki, Fred Y.
    Schwarz, Tino F.
    Poppe, Willy A. J.
    Xavier Bosch, F.
    Harper, Diane M.
    Huh, Warner
    Hardt, Karin
    Zahaf, Toufi K.
    Descamps, Dominique
    Struyf, Frank
    Dubin, Gary
    Lehtinen, Matti
    [J]. LANCET ONCOLOGY, 2012, 13 (01) : 100 - 110